return to news
  1. NATCO shares rally over 4% after partner Mylan settles patent litigation with Novo Nordisk over Ozempic in US

Market News

NATCO shares rally over 4% after partner Mylan settles patent litigation with Novo Nordisk over Ozempic in US

PTI.jpg

1 min read | Updated on October 07, 2024, 11:23 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Shares of NATCO Pharma surged over 4% to an intraday high of ₹1,412.95 on the NSE after the company announced a patent litigation settlement between its partner Mylan and Novo Nordisk regarding the generic version of Ozempic, a diabetes and weight loss medication.

Stock list

 NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products

NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products

Shares of NATCO Pharma Ltd rallied more than 4% and were trading at a intraday-high of ₹1,412.95 on the NSE on Monday.

This comes after NATCO on Monday announced that its partner Mylan Pharmaceuticals Inc has reached a patent litigation settlement with Novo Nordisk in the US over generic Ozempic, a drug used to lower blood sugar and weight loss.

NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing.

Ozempic is a prescription medication patented by Novo Nordisk.

"Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)," NATCO said in the filing.

The terms of the settlement are confidential, it added.

Novo Nordisk had filed a patent infringement suit against Mylan over Ozempic in a US court.

As of 11:02 am the stock was trading at ₹1,354.35 per share, up by 0.03% (or ₹0.40) on the NSE.

About The Author

PTI.jpg
Press Trust of India (PTI) is India's premier news agency.

Next Story